CryptoMedix

CryptoMedix is a private U.S. oncology-focused biotechnology company developing immuno-oncology therapeutics that target the tumor microenvironment. The company describes its lead approach as first-in-class therapeutic antibodies designed to enhance cytotoxic T-cell migration and function while reducing tumor-supportive macrophage activity in tumors. Its disclosed programs include CMX-101 and CMX-102, with CMX-102 also described as potentially suitable for antibody-drug conjugate or radionuclide-conjugate applications. Company materials and third-party profiles indicate an early-stage, preclinical pipeline and an active search for funding and strategic partnerships to advance development.